← 返回

研究人γδ T 细胞治疗效力的临床前平台

英文原题:Preclinical platforms to study therapeutic efficacy of human γδ T cells.

查看英文原题

Preclinical platforms to study therapeutic efficacy of human γδ T cells.

PubMed 2022/06/01(内容时间) Clin Transl Med Q1 · IF 7.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

肿瘤浸润性γδ T 细胞在黑色素瘤 3D 模型中表现出耗竭的免疫表型和有限的抗肿瘤能力。检查点抑制剂和表观遗传修饰剂增强γδ T 细胞的抗肿瘤功能。这四种 3D 模型为测试γδ T 细胞免疫治疗功能提供了有价值的临床前平台。

研究思路结论见上方概要

γδ T淋巴细胞是过继性T细胞治疗的有前景的候选者,然而其治疗效果并不令人满意。Vδ2 T细胞为灵长类所特有,且可用于检测其抗肿瘤功能的合适模型很少。

我们在四种三维(3D)模型中测试了人类γδ T细胞的活化、肿瘤浸润和肿瘤杀伤能力,包括单细胞、双细胞和多细胞黑色素瘤球体,以及患者来源的黑色素瘤类器官。我们研究了检查点抑制剂对γδ T细胞的影响,并利用这些平台进行了小分子筛选。

γδ T细胞对黑色素瘤细胞快速应答,并且比PBMCs中的αβ T细胞更好地浸润黑色素瘤球体。双细胞球体中的癌症相关成纤维细胞(CAFs)、多细胞黑色素瘤球体中的基质细胞以及类器官中的抑制性免疫细胞显著抑制包括γδ T细胞在内的免疫细胞浸润,并降低其对肿瘤细胞的细胞毒性。肿瘤浸润性γδ T细胞表现出耗竭的免疫表型,伴有高检查点表达(CTLA-4、PD-1和PD-L1)。免疫检查点抑制剂增加了γδ T细胞对3D模型的浸润以及对黑色素瘤细胞的杀伤,在全部四种3D模型中均如此。我们的 小分子筛选试验及后续机制研究表明,表观遗传修饰剂通过上调MICA/B、抑制HDAC6/7通路以及下调CAFs和肿瘤细胞中PD-L1和PD-L2的水平,增强了γδ T细胞的趋化和细胞毒性。这些化合物增加了γδ T细胞的CXCR4和CD107a表达、IFN-γ产生,并降低了PD-1表达。

展开英文摘要原文

Gamma delta (γδ) T lymphocytes are promising candidate for adoptive T cell therapy, however, their treatment efficacy is not satisfactory. Vδ2 T cells are unique to primates and few suitable models are available to assay their anti-tumour function.

We tested human γδ T cell activation, tumour infiltration, and tumour-killing in four three-dimensional (3D) models, including unicellular, bicellular and multicellular melanoma spheroids, and patient-derived melanoma organoids. We studied the effects of checkpoint inhibitors on γδ T cells and performed a small molecule screen using these platforms.

γδ T cells rapidly responded to melanoma cells and infiltrated melanoma spheroids better than αβ T cells in PBMCs. Cancer-associated fibroblasts (CAFs) in bicellular spheroids, stroma cells in multicellular melanoma spheroids and inhibitory immune cells in organoids significantly inhibited immune cell infiltrates including γδ T cells and lessened their cytotoxicity to tumour cells. Tumour-infiltrating γδ T cells showed exhausted immunophenotypes with high checkpoints expression (CTLA-4, PD-1 and PD-L1). Immune checkpoint inhibitors increased γδ T cell infiltration of 3D models and killing of melanoma cells in all four 3D models. Our small molecule screen assay and subsequent mechanistic studies demonstrated that epigenetic modifiers enhanced the chemotaxis and cytotoxicity of γδ T cells through upregulating MICA/B, inhibiting HDAC6/7 pathway and downregulating the levels of PD-L1 and PD-L2 in CAFs and tumour cells. These compounds increased CXCR4 and CD107a expression, IFN-γ production and decreased PD-1 expression of γδ T cells.

Tumour-infiltrating γδ T cells show exhausted immunophenotypes and limited anti-tumour capacity in melanoma 3D models. Checkpoint inhibitors and epigenetic modifiers enhance anti-tumour functions of γδ T cells. These four 3D models provided valuable preclinical platforms to test γδ T cell functions for immunotherapy.

论文信息

作者
Ou L、Wang H、Huang H、Zhou Z、Lin Q、Guo Y、Mitchell T、Huang AC
单位
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.United States
文献类型
美国 NIH 资助研究 · 非美国政府资助研究
期刊
Clinical and translational medicine2022 Jun
原文标识
PubMed 35731974 · DOI 10.1002/ctm2.814